Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma
NCT01661881Phase 2Active, not recruiting
- Start
- Aug 2012
- Primary completion
- Feb 2015
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, bendamustine and cytarabine in mantle cell lymphoma (MCL). Primary endpoint: Complete Remission Rate at 25 weeks. Started Aug 2012; status: active, not recruiting.
02
Drugs
rituximabbendamustinecytarabine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01661881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661881.